Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
about
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma.Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety.
P2860
Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Risk score model for the devel ...... tment for chronic hepatitis B.
@ast
Risk score model for the devel ...... tment for chronic hepatitis B.
@en
type
label
Risk score model for the devel ...... tment for chronic hepatitis B.
@ast
Risk score model for the devel ...... tment for chronic hepatitis B.
@en
prefLabel
Risk score model for the devel ...... tment for chronic hepatitis B.
@ast
Risk score model for the devel ...... tment for chronic hepatitis B.
@en
P2093
P2860
P356
P1476
Risk score model for the devel ...... tment for chronic hepatitis B.
@en
P2093
Hyung Joon Kim
Ji Hoon Kim
Ju-Yeon Cho
Jung Il Lee
Min-Ah Woo
Sin-Ho Jung
P2860
P304
P356
10.3350/CMH.2016.0086
P577
2017-05-16T00:00:00Z